IRVINE, Calif., April 18, 2013 /PRNewswire/ -- ChromaDex Corporation® (OTCQB: CDXC) ("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the initiation of the first human clinical study in the U.S. for PURENERGY.
PURENERGY is a patented co-crystal ingredient comprised of caffeine and ChromaDex's pTeroPure®pterostilbene that forms a unique crystalline structure having superior benefits as compared to the two individual components alone. Recently, caffeinated energy products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts of caffeine. This patented new ingredient technology should allow formulators of caffeinated energy products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.
The human study is intended to confirm an earlier animal study which showed PURENERGY had a 6-8 times longer half-life as compared to caffeine alone.1 The results of the animal study suggest that PURENERGY may provide longer sustained energy and alertness with reduced amounts of caffeine and without the "crash" typically experienced when ingesting caffeinated energy products.
The clinical trial is designed to determine the safety, relative bioavailability and pharmacokinetics of PURENERGY as compared to pterostilbene and caffeine alone. The start of this trial in the U.S. follows the recent commercial launch of PURENERGY.
Frank Jaksch, co-founder and CEO of ChromaDex stated, "The study will provide valuable insight about the benefits of PURENERGY and be an important addition to the previously successful animal study. We believe the introduction of PURENERGY is timely given the current regulatory scrutiny of caffeinated energy products."
Given the co-crystal formulation with pTeroPure, PURENERGY also has additional functional health benefits that include cognitive function, antioxidant activity, heart health and weight management support. ChromaDex's patented pTeroPure is a 99 percent pure nature identical pterostilbene with seven patents pending or issued. pTeroPure was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan. PURENERGY and pTeroPure are manufactured exclusively for ChromaDex by Laurus Labs, one of the leaders in API manufacturing.
1 Data on File
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly-owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The Company provides seamless science-based solutions to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure® pterostilbene; ProC3G, a natural black rice containing cyanidine-3-glucoside; PURENERGY, a caffeine-pTeroPure co-crystal; nutraGac, a gac fruit powder; curcumin, and nicotinamide riboside, a novel next-generation B-vitamin currently under development. To learn more about ChromaDex please visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Media Inquiries:
Chandler Chicco Agency
Keshia Cain, Media Specialist
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
Laura Carney, Executive Assistant
These statements in this press release have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
SOURCE ChromaDex Corporation